TNFRSF17 and neoplasm: While anti-BCMA and anti-TACI–anti-BCMA CARs had limited activity against the tumor cells, anti-TACI and anti-BCMA–anti-TACI CARs had a significant increase in CAR expansion and activation (Fig. 8i, j).